HIGHLIGHTS
- who: . Reynold Panettieri and colleagues from the Reynold, Rutgers University, Brunswick, USA have published the Article: Pharmacological treatment and current controversies in COPD [version 1; peer review: 3 approved], in the Journal: (JOURNAL)
- what: If the outcome was the risk of moderate or severe ECOPDs or the change from baseline in trough FEV1, LAMA/LABA/ICS resulted in significantly better outcomes than LAMA/LABA and single long-acting bronchodilator, whereas when the analysis was focused on the risk of pneumonia, no significant differences were observed.
SUMMARY
A systematic review with meta . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.